EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Lichenoid graft‐versus‐host disease shows a high interferon score, with IFNAR1 inhibition preventing skin inflammation

Chloé Grolleau iD, Thomas Poisot, Andreea Calugareanu iD, Regis Peffault De Latour, Marie Robin, David Michonneau, Flore Sicre de Fontbrune, Adèle de Masson iD, Maxime Battistella, Gerard Socié, Hélène Le Buanec, Jean-David Bouaziz iD

Journal of the European Academy of Dermatology and Venereology · 2025

DOI: 10.1111/jdv.20760 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of the European Academy of Dermatology and Venereology, 2025. Verfasst von Chloé Grolleau und 11 weiteren Autor:innen. Beteiligte Einrichtung: Dermatology Department, Hôpital Saint Louis, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France. Hauptthemen laut MEDLINE: Graft vs Host Disease, Receptor, Interferon alpha-beta, Interferon Type I, Lichenoid Eruptions. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Société de Recherche en Dermatologie, Agence de Biomédecine, Société francaise de dermatologie et vénérologie.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Chronic cutaneous graft‐versus‐host disease (ccGVHD) is a debilitating complication of allogeneic haematopoietic stem cell transplantation, manifesting as either sclerotic or lichenoid eruptions (lGVHD). Although frequent, the pathogenesis of lGVHD remains mainly unknown and represents a therapeutic challenge.

Objectives

This study aims to decipher the immunological mechanisms underlying lichenoid GVHD and to evaluate the effect of blocking the Type I interferons (IFN‐I) pathway in a mice model of ccGVHD on local inflammation.

Methods

First, we performed single‐cell gene expression analysis (scRNA‐Seq) of human lGVHD skin samples ( n = 3) compared with healthy control ( n = 4) and analysed the distribution and inflammatory signatures of immune cells. Results were confronted with bulk‐RNA‐Seq data of an independent cohort of lGVHD ( n = 8) previously published by our group to compare the predicted immune population within lGVHD skin through deconvolution analyses. The IFN‐I score was assessed through quantitative PCR on lGVHD lesions ( n = 13) compared with HC ( n = 10). Secondly, we analysed publicly available skin microarray data from a mouse model of ccGVHD, in which allografted mice were treated with an anti‐IFNAR1 antibody targeting the Type I interferon receptor.

Results

ScRNA‐Seq analysis of human immune cells revealed a strong Type I and II interferons signature in lGVHD skin, along with an increased expression of T h2 /T h17 and activation markers in T cells and macrophages, respectively. Consistent with our human data, murine skin GVHD samples were characterized by interferon and allograft inflammatory responses, which were greatly prevented by early infusions of anti‐IFNAR1 antibody after allograft. Bioinformatic analyses highlighted interferons, along with T h2 and T h17 markers, as putative key regulators in mice skin inflammation that were also diminished or abrogated consequently to early anti‐IFNAR1 antibody infusions.

Conclusions

Together, our data suggests that interferon pathways, and in particular Type I via IFNAR1, may be promising therapeutic targets for the treatment of lichenoid chronic GVHD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Graft vs Host DiseaseReceptor, Interferon alpha-betaInterferon Type ILichenoid EruptionsAnimalsHumansMiceDisease Models, AnimalFemaleMaleHematopoietic Stem Cell Transplantation

Substanzen

Receptor, Interferon alpha-betaInterferon Type IIFNAR1 protein, human

Autor:innen und Institutionen

  • Dermatology Department, Hôpital Saint Louis, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France.
  • Université Paris Cité, INSERM U976 - HIPI Unit, Institut de Recherche Saint-Louis, Paris, France.
  • Dermatology Department, Hôpital Emile Muller, GHR Mulhouse Sud Alsace, Mulhouse, France.
  • Hématologie/Transplantation, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France.
  • Pathology Department, Hôpital Saint Louis, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France.

ORCID-Profile: Chloé Grolleau, Andreea Calugareanu, Adèle de Masson, Jean-David Bouaziz

Förderung

  • Société de Recherche en Dermatologie
  • Agence de Biomédecine
  • Société francaise de dermatologie et vénérologie
  • AstraZeneca

Zitieren

APA

Grolleau, C., Poisot, T., Calugareanu, A., Peffault De Latour, R., Robin, M., Michonneau, D., Sicre de Fontbrune, F., de Masson, A., Battistella, M., Socié, G., Le Buanec, H., & Bouaziz, J. D. (2025). Lichenoid graft‐versus‐host disease shows a high interferon score, with IFNAR1 inhibition preventing skin inflammation. Journal of the European Academy of Dermatology and Venereology. https://doi.org/10.1111/jdv.20760

Vancouver

Grolleau C, Poisot T, Calugareanu A, Peffault De Latour R, Robin M, Michonneau D, et al. Lichenoid graft‐versus‐host disease shows a high interferon score, with IFNAR1 inhibition preventing skin inflammation. Journal of the European Academy of Dermatology and Venereology. 2025. doi:10.1111/jdv.20760

BibTeX
@article{Grolleau2025,
  author = {Grolleau, Chloé and Poisot, Thomas and Calugareanu, Andreea and Peffault De Latour, Regis and Robin, Marie and Michonneau, David and Sicre de Fontbrune, Flore and de Masson, Adèle and Battistella, Maxime and Socié, Gerard and Le Buanec, Hélène and Bouaziz, Jean-David},
  title = {Lichenoid graft‐versus‐host disease shows a high interferon score, with IFNAR1 inhibition preventing skin inflammation},
  journal = {Journal of the European Academy of Dermatology and Venereology},
  year = {2025},
  doi = {10.1111/jdv.20760}
}
Kostenlos starten →